AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01054352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342
Description: multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
Study NCT01054352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: up to four (4) additional cohorts consisting of healthy male volunteers may be added
Study NCT01054352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: .up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
Study NCT01054352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
Study NCT02626104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin
Description: The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
Study NCT02626104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
Study NCT02614872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLASSIA® and Institution standard of care (SOC)
Description: Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
Study NCT02523326 — intervention group
Intervention type: DEVICE
Intervention: saliva samples obtained with mouthwash
Description: saliva samples obtained with mouthwash
Study NCT02090764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06561802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF and saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
Study NCT01196169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
Study NCT01196169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if > one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
Study NCT03003663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensableCare System
Description: The SensableCare System is evaluated for reducing bed falls.
Study NCT01528592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa
Description: Equivalent amount of carbidopa-levodopa will be provide to you
Study NCT01047540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: Oral administration
Study NCT01047540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT01854450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetrical Lateral Decubitus
Description: After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position
Study NCT01854450 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: usual obstetrical care
Study NCT03557853 — intervention group
Intervention type: DRUG
Intervention: Golimumab Injection
Description: Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
Study NCT01949831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of functional ability in combination with follow-up at home
Study NCT02506465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTIND
Description: Temporary Implantable Nitinol Device (iTIND)
Study NCT00492544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™ (HPV-16/18 L1 VLP AS04)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT01914588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
Study NCT01914588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: * Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits
Study NCT02506465 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Arm
Description: Foley catheter will be placed and immediately removed.
Study NCT03959553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT
Study NCT03959553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline
Study NCT01914588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: * Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits
Study NCT00809393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg
Study NCT00809393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: 30 mg/kg
Study NCT04759573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Vocal Contact
Description: Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
Study NCT04759573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Observation
Description: Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
Study NCT03758378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
Study NCT03060889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
Study NCT01399853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml EV71 Vaccine
Description: inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
Study NCT01399853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml EV71 vaccine
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
Study NCT01399853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
Study NCT01399853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (without adjuvant) 640U /0.5ml
Description: inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
Study NCT02237131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptives cyclic
Description: tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
Study NCT02237131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptives cyclic
Description: tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
Study NCT01399853 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 28 days interval
Study NCT01198626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-32729463
Description: 150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
Study NCT01198626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
Study NCT02237131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptives continuous
Description: Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
Study NCT02237131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptives continuous
Description: Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
Study NCT01459081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg inhaled by mouth, twice daily, for 5 days
Study NCT01459081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhaled by mouth, twice daily, for 5 days
Study NCT01352104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEP-TE
Description: PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses.
Study NCT00990405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprzole+Amoxicillin+Clarithromycin
Description: Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
Study NCT01198626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-32729463 (Open-Label)
Description: Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
Study NCT03470025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: 1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR.
Study NCT04883268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon
Description: Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
Study NCT03530358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-aided rehabilitation
Description: VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target.
Study NCT03530358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
Study NCT02846324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish orange
Study NCT02846324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT04328766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202005, alone
Description: DWC202005, as a single dose
Study NCT03945045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subclavian vein approach
Description: Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
Study NCT03641092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringParenting Intervention
Description: The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
Study NCT03641092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Well Child Care
Description: The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
Study NCT03575897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of infant body composition
Description: Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
Study NCT03575897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of infant body composition
Description: Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
Study NCT04328766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 + DWC202005
Description: DWP14012 and DWC202005, as a single dose
Study NCT03945045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal jugular vein approach
Description: internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
Study NCT01835496 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: single 1500 mg dose of Ferriprox
Description: A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
Study NCT04328766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 + DWC202005, after multiple doses of DWP14012
Description: DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Study NCT03873025 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and CXD101
Description: Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
Study NCT04356612 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
Study NCT04666324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: Oral daily treatment for four weeks
Study NCT04666324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multilac Baby
Description: Oral daily treatment for four weeks
Study NCT03141086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134
Study NCT03141086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT02273232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
Study NCT02273232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise
Description: constructed extra excessive for peripheral vascular diastase patients
Study NCT02029664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual distortion increment based on the gait pattern
Study NCT01813825 — intervention group
Intervention type: OTHER
Intervention: Registry
Study NCT02457507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 2 tablets
Study NCT02457507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets
Study NCT00128193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
Study NCT00128193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
Study NCT00810862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus active cream
Description: Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
Study NCT00810862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo base cream
Description: apply to affected study area twice daily for 21 days
Study NCT02927834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 day Prednisone
Description: 6 day prednisone burst
Study NCT02927834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Antibiotic augmentin for 3 weeks
Study NCT02927834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21 day Prednisone
Description: 21 day prednisone burst
Study NCT02740179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 50mg by mouth twice daily
Study NCT02740179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice daily
Study NCT02740179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: Counseling regarding diet and healthy activity
Study NCT02740179 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: Counseling regarding diet and healthy activity